CN105012230B - 一种依达拉奉的药物组合物 - Google Patents
一种依达拉奉的药物组合物 Download PDFInfo
- Publication number
- CN105012230B CN105012230B CN201410179334.XA CN201410179334A CN105012230B CN 105012230 B CN105012230 B CN 105012230B CN 201410179334 A CN201410179334 A CN 201410179334A CN 105012230 B CN105012230 B CN 105012230B
- Authority
- CN
- China
- Prior art keywords
- edaravone
- pharmaceutical composition
- sodium chloride
- acetic acid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical group O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 229950009041 edaravone Drugs 0.000 title claims abstract description 68
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 68
- 239000011780 sodium chloride Substances 0.000 claims abstract description 34
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 239000000243 solution Substances 0.000 claims description 39
- 238000003756 stirring Methods 0.000 claims description 36
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 24
- 239000007974 sodium acetate buffer Substances 0.000 claims description 22
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 21
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 20
- 239000003978 infusion fluid Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000008215 water for injection Substances 0.000 claims description 14
- 238000001802 infusion Methods 0.000 claims description 12
- 239000003610 charcoal Substances 0.000 claims description 11
- 210000004907 gland Anatomy 0.000 claims description 11
- 239000012982 microporous membrane Substances 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000012535 impurity Substances 0.000 abstract description 27
- 239000007853 buffer solution Substances 0.000 abstract description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 7
- 229910052708 sodium Inorganic materials 0.000 abstract description 7
- 239000011734 sodium Substances 0.000 abstract description 7
- 230000014759 maintenance of location Effects 0.000 abstract description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 description 27
- 230000003078 antioxidant effect Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 10
- 239000003643 water by type Substances 0.000 description 10
- 208000026106 cerebrovascular disease Diseases 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000003002 pH adjusting agent Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- OLFJVIXNILIZKF-UHFFFAOYSA-N acetic acid;sodium Chemical compound [Na].CC(O)=O.CC(O)=O OLFJVIXNILIZKF-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004176 ammonification Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 241000385540 bacterium 10 Species 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005262 decarbonization Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000007731 hot pressing Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410179334.XA CN105012230B (zh) | 2014-04-30 | 2014-04-30 | 一种依达拉奉的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410179334.XA CN105012230B (zh) | 2014-04-30 | 2014-04-30 | 一种依达拉奉的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105012230A CN105012230A (zh) | 2015-11-04 |
CN105012230B true CN105012230B (zh) | 2018-01-16 |
Family
ID=54402789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410179334.XA Active CN105012230B (zh) | 2014-04-30 | 2014-04-30 | 一种依达拉奉的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105012230B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1449754A (zh) * | 2003-04-16 | 2003-10-22 | 浙江震元制药有限公司 | 依达拉奉药物组合物及制备 |
CN102091028A (zh) * | 2009-12-15 | 2011-06-15 | 南京长澳医药科技有限公司 | 一种依达拉奉注射液及其制备方法 |
CN102119920A (zh) * | 2010-07-13 | 2011-07-13 | 福建天泉药业股份有限公司 | 一种依达拉奉注射液及制备方法 |
JP2011136973A (ja) * | 2009-12-28 | 2011-07-14 | Keiki Imoto | 安定なエダラボン含有水性製剤 |
CN102144964A (zh) * | 2010-07-02 | 2011-08-10 | 南京长澳医药科技有限公司 | 一种稳定安全的依达拉奉注射液 |
WO2011111070A2 (en) * | 2010-03-09 | 2011-09-15 | Bdr Pharmaceuticals International Pvt. Ltd. | Novel injectable combination |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010047482A (ja) * | 2008-08-19 | 2010-03-04 | Ohara Yakuhin Kogyo Kk | エダラボン注射液 |
JP2010077104A (ja) * | 2008-08-29 | 2010-04-08 | Nihon Pharmaceutical Co Ltd | 3−メチル−1−フェニル−2−ピラゾリン−5−オン注射用水溶液 |
-
2014
- 2014-04-30 CN CN201410179334.XA patent/CN105012230B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1449754A (zh) * | 2003-04-16 | 2003-10-22 | 浙江震元制药有限公司 | 依达拉奉药物组合物及制备 |
CN102091028A (zh) * | 2009-12-15 | 2011-06-15 | 南京长澳医药科技有限公司 | 一种依达拉奉注射液及其制备方法 |
JP2011136973A (ja) * | 2009-12-28 | 2011-07-14 | Keiki Imoto | 安定なエダラボン含有水性製剤 |
WO2011111070A2 (en) * | 2010-03-09 | 2011-09-15 | Bdr Pharmaceuticals International Pvt. Ltd. | Novel injectable combination |
CN102144964A (zh) * | 2010-07-02 | 2011-08-10 | 南京长澳医药科技有限公司 | 一种稳定安全的依达拉奉注射液 |
CN102119920A (zh) * | 2010-07-13 | 2011-07-13 | 福建天泉药业股份有限公司 | 一种依达拉奉注射液及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105012230A (zh) | 2015-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100522163C (zh) | 长春西汀小容量注射剂及其制备工艺 | |
CN103432070B (zh) | 左乙拉西坦注射液和制法 | |
EP1702612B1 (en) | Soft capsule containing butylphthalide and its preparation procedure | |
CN1440749A (zh) | 易达拉封注射剂及其制备工艺——治疗急性脑梗塞 | |
CN109662950A (zh) | 一种含有盐酸达泊西汀的药物组合物 | |
CN103385876B (zh) | 一种夫罗曲坦的药物组合物及其制备方法 | |
WO2024027267A1 (zh) | 一种环孢素a制剂中有关物质的分析方法及其应用 | |
CN105012230B (zh) | 一种依达拉奉的药物组合物 | |
CN1915986A (zh) | 一种高纯度的丹参酮iia磺酸钠、制备方法及其制剂 | |
CN102636600B (zh) | 一种测定盐酸帕洛诺司琼组合物中光学异构体的方法 | |
CN102038680B (zh) | 一种药用组合物 | |
CN103860461B (zh) | 一种含有活性成分盐酸氨溴索的药物组合物 | |
Besner et al. | Pharmacokinetics of lonidamine after oral administration in cancer patients | |
CN110196299B (zh) | 复视明胶囊的指纹图谱及其在质量控制与成分分析中的应用 | |
CN105030708B (zh) | 一种利鲁唑片及其制备方法 | |
CN103405384A (zh) | 氨甲环酸的药物组合物 | |
CN104072400B (zh) | 一种奥拉西坦化合物及其药物组合物 | |
CN105001202B (zh) | 一种埃索美拉唑钠化合物及其药物组合物 | |
CN105770144A (zh) | 复方鱼腥草糖浆及其治疗脑脊髓炎的制药用途及检测方法 | |
CN103385862B (zh) | 一种酒石酸美托洛尔缓释片及其制备方法 | |
CN103159710A (zh) | 用于抗病毒的十氢萘衍生物 | |
CN105147664B (zh) | 葛根素注射液及制备方法 | |
CN105380912B (zh) | 一种含有他达拉非的药物组合物 | |
CN114917213B (zh) | 包含阿米替林的精神疾病治疗剂和治疗精神疾病的方法 | |
CN104644558A (zh) | 一种西尼地平的固体分散体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant after: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Address before: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant before: Changchun Haiyue Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug combination of edaravone Effective date of registration: 20231226 Granted publication date: 20180116 Pledgee: China Construction Bank Co.,Ltd. Changchun Science and Technology Sub branch Pledgor: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023220000149 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |